Founded in 1985, GSP Crop Science Limited has established itself as a significant player in the agrochemical sector, specializing in the development and manufacture of insecticides, herbicides, fungicides, and plant growth regulators. The company operates a vertically integrated business model, producing both Technicals (concentrated active ingredients) and Formulations (end-use products) to enhance agricultural productivity.

GSP’s competitive edge is rooted in its robust R&D capabilities, supported by dedicated facilities in Kathwada and Odhav. As of March 2026, the company’s innovation pipeline is evidenced by 102 granted patents and over 500 product registrations. With a strong domestic presence spanning 20 Indian states, GSP has also successfully scaled its international footprint across 37 countries, including key markets in North America, Latin America, and the Asia-Pacific region. By balancing proprietary branding with licensed manufacturing, GSP continues to capture value across the global agricultural supply chain.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Well-diversified product portfolio including a wide range of insecticides, herbicides, fungicides, and plant growth regulators, making us a comprehensive solution provider for the customers.
• Catering to a large and diverse clientele both domestically as well as internationally.
• Strong in-house R&D capabilities with focus on innovation and product development
• Robust manufacturing facilities with ability to manufacture a wide range of products with a focus on sustainability.
• Led by qualified and experienced Promoters and supported by a professional management team

The Company GSP CROP SCIENCE LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Repayment or pre-repayment of all or a portion of certain outstanding borrowings availed by the Company (Rs. 170 Cr.)
• General Corporate Purpose

At the upper band of IPO Rs. 320, the stock is valued at 9.18 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.